Article Information
PubMed
Published By
History
- Received September 18, 2018
- Returned for modification October 29, 2018
- Accepted January 19, 2019
- Published online March 27, 2019.
Copyright & Usage
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (February 11, 2019).
- You are viewing the most recent version of this article.
Author Information
- aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- bCollege of Life Sciences, Shanghai Normal University, Shanghai, China
- cPhase I Unit, Huashan Hospital, Fudan University, Shanghai, China
- dShanghai Jiaotong University, Shanghai, China
- eBiomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Melbourne, Australia
- Address correspondence to Jing Zhang, zhangj_fudan{at}aliyun.com.
X.B. and X.L. contributed equally to the manuscript.
Citation Bian X, Liu X, Chen Y, Chen D, Li J, Zhang J. 2019. Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 63:e01989-18. https://doi.org/10.1128/AAC.01989-18.